



Küpers, L. K., Monnereau, C., Sharp, G. C., Yousefi, P., Salas, L. A., Ghantous, A., Page, C. M., Reese, S. E., Wilcox, A. J., Czamara, D., Starling, A. P., Novoloaca, A., Lent, S., Roy, R., Hoyo, C., Breton, C. V., Allard, C., Just, A. C., Bakulski, K. M., ... Felix, J. F. (2019). Meta-analysis of epigenome-wide association studies in neonates reveals widespread differential DNA methylation associated with birthweight. *Nature Communications*, 10(1), [1893].
<https://doi.org/10.1038/s41467-019-09671-3>

Publisher's PDF, also known as Version of record

License (if available):
CC BY

Link to published version (if available):
[10.1038/s41467-019-09671-3](https://doi.org/10.1038/s41467-019-09671-3)

[Link to publication record in Explore Bristol Research](#)
PDF-document

This is the final published version of the article (version of record). It first appeared online via Springer Nature at <https://www.nature.com/articles/s41467-019-09671-3>. Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

ARTICLE

<https://doi.org/10.1038/s41467-019-09671-3>

OPEN

Meta-analysis of epigenome-wide association studies in neonates reveals widespread differential DNA methylation associated with birthweight

Leanne K. Küpers et al.[#]

Birthweight is associated with health outcomes across the life course, DNA methylation may be an underlying mechanism. In this meta-analysis of epigenome-wide association studies of 8,825 neonates from 24 birth cohorts in the Pregnancy And Childhood Epigenetics Consortium, we find that DNA methylation in neonatal blood is associated with birthweight at 914 sites, with a difference in birthweight ranging from −183 to 178 grams per 10% increase in methylation ($P_{\text{Bonferroni}} < 1.06 \times 10^{-7}$). In additional analyses in 7,278 participants, <1.3% of birthweight-associated differential methylation is also observed in childhood and adolescence, but not adulthood. Birthweight-related CpGs overlap with some Bonferroni-significant CpGs that were previously reported to be related to maternal smoking (55/914, $p = 6.12 \times 10^{-74}$) and BMI in pregnancy (3/914, $p = 1.13 \times 10^{-3}$), but not with those related to folate levels in pregnancy. Whether the associations that we observe are causal or explained by confounding or fetal growth influencing DNA methylation (i.e. reverse causality) requires further research.

Correspondence and requests for materials should be addressed to D.A.L. (email: d.a.Lawlor@bristol.ac.uk) or to C.L.R. (email: caroline.relton@bristol.ac.uk) or to H.S. (email: h.snieder@umcg.nl) or to J.F.F. (email: j.felix@erasmusmc.nl). [#]A full list of authors and their affiliations appears at the end of the paper.

Intrauterine exposures, such as maternal smoking, pre-pregnancy body mass index (BMI), hyperglycaemia, hypertension, folate and famine are associated with fetal growth and hence birthweight^{1–6}. Observational studies show that birthweight is also associated with later-life health outcomes, including cardio-metabolic and mental health, some cancers and mortality^{7–11}. In these long-term associations, birthweight may act as a proxy for potential effects of intrauterine exposures^{12,13}. Several mechanisms may explain the associations of intrauterine exposures with birthweight and later-life health as we illustrate in Fig. 1. Our overall conceptual framework in this study was that the intrauterine environment induces epigenetic alterations, which influence fetal growth and hence correlate with birthweight. This is partly supported by previous large-scale epigenome-wide association studies (EWAS) that have reported associations of relevant maternal pregnancy exposures, including smoking, air pollution and BMI, with DNA methylation in offspring neonatal blood^{14–16}. However, whilst four previous EWAS have observed associations of DNA methylation with birthweight^{17–20}, the evidence to date has been limited in scale and power with sample sizes ranging from approximately 200 to 1000.

In this study, we hypothesised that there are associations between DNA methylation and birthweight. We further aimed to explore if these epigenetic alterations are associated with later disease outcomes (Fig. 1). If birthweight is a proxy for a range of adverse prenatal exposures, we might expect neonatal blood DNA methylation to be associated with birthweight. However, we acknowledge that any associations of DNA methylation with birthweight may be explained by confounding²¹ or reflect fetal growth influencing DNA methylation.

Here we present a large meta-analysis of multiple EWAS to explore associations between neonatal blood DNA methylation and birthweight. In further analyses, we explore whether any birthweight-associated differential methylation persists at older ages. To aid functional interpretation, we (i) explore the overlap of identified cytosine-phosphate-guanine sites (CpGs) that are differentially methylated in relation to birthweight with those known to be associated with intrauterine exposure to smoking, famine and different levels of BMI and folate; (ii) associate DNA methylation at identified CpGs with gene expression and (iii) explore potential causal links with birthweight and later-life health using Mendelian randomization (MR)²². We show that DNA methylation in neonatal blood is associated with birthweight and some of the differential methylation is also observed in childhood and adolescence, but not in adulthood.

Also, we show overlap between birthweight-related CpGs and CpGs related to intrauterine exposures. Potential causality of the associations needs to be studied further.

Results

Participants. We used data from 8825 neonates from 24 studies in the Pregnancy And Childhood Epigenetics (PACE) Consortium, representing mainly European, but also African and Hispanic ethnicities with similar proportions of males and females. Details of participants used in all analyses are presented in Table 1, Supplementary Data 1 and study-specific Supplementary Methods.

Meta-analysis. Primary, secondary and follow-up analyses are outlined in the study design in Fig. 2. Methylation at 8170 CpGs, measured in neonatal blood using the Illumina Infinium® Human-Methylation450 BeadChip assay and adjusted for cell-type heterogeneity^{23–25}, was associated with birthweight (false discovery rate (FDR) <0.05), of which 1029 located in or near 807 genes survived the more stringent Bonferroni correction ($p < 1.06 \times 10^{-7}$, Supplementary Data 2). We observed both positive (45%) and negative (55%) directions of associations between methylation levels of these 1029 CpGs and birthweight (Fig. 3) and these CpGs were spread throughout the genome (orange track (1) in Fig. 4 and Supplementary Fig. 1). We found evidence of between-study heterogeneity ($I^2 > 50\%$) for 115 of the 1029 sites (Supplementary Data 2), thus we prioritised 914 CpGs, located in or near 729 genes, based on $p < 1.06 \times 10^{-7}$ and $I^2 \leq 50\%$ for further analyses (Fig. 3 and orange track (1) in Fig. 4). The CpG with the largest positive association was cg06378491 (in the gene body of *MAP4K2*). For each 10% increase in methylation at this site, birthweight was 178 g higher (95% confidence interval (CI): 138, 218 g). The CpG with the largest negative association was cg10073091 (in the gene body of *DHCR24*), which showed a 183 g decrease in birthweight per 10% increase in methylation (95% CI: –225, –142 g). The CpG with the smallest P -value and $I^2 \leq 50\%$ was cg17714703 (in the gene body of *UHRF1*), which showed a 130 g increase in birthweight for 10% increase in methylation (95% CI: 109, 151 g).

Findings were consistent with results from our main analyses when restricted to participants of European ethnicity, with a Pearson correlation coefficient for effect estimates of 0.99 for the 914 birthweight-associated CpGs (Supplementary Fig. 2, blue track (2) in Fig. 4 and Supplementary Data 3) and 0.90 for all 450k CpGs. Comparing the main meta-analysis to the four Hispanic cohorts and




Fig. 1 Hypothetical paths that might link intrauterine exposures to DNA methylation, birthweight and later-life health outcomes. Red arrows summarise the paths that have motivated the analyses undertaken in this study (i.e. that maternal environmental exposures influence DNA methylation that in turn influences fetal growth and hence birthweight). The EWAS meta-analysis undertaken sought to identify methylation associated with birthweight. Blue arrows summarise other plausible paths, including that maternal exposures influence fetal growth first and it then influences DNA methylation or that maternal exposures may influence fetal growth/birthweight and later-life health outcomes through other pathways than DNA methylation

Table 1 Characteristics for the participating studies in the main meta-analysis for the association between neonatal blood DNA methylation and birthweight

Study	Total N	Normal birthweight, N (%)	High birthweight, N (%)	Birthweight (g)	Gestational age (wk)	Ethnicity	Boys, N (%)
ALSPAC	633	547 (86.4)	79 (12.5)	3512 ± 443	39.7 ± 1.3	European	301 (47.6)
CBC ^a : Hispanic	127	106 (83.5)	19 (15.0)	3445 ± 484	39.8 ± 1.3	Hispanic	74 (58.3)
CBC ^a : Caucasian	136	108 (79.4)	26 (19.1)	3625 ± 472	39.7 ± 1.5	European	79 (58.1)
CHAMACOS	283	236 (83.4)	44 (15.5)	3520 ± 446	39.3 ± 1.2	Hispanic	142 (50.1)
CHS ^a	199	168 (84.4)	28 (14.1)	3486 ± 476	40.2 ± 1.2	Mixed	79 (39.7)
EARLI	131	113 (86.3)	16 (12.2)	3507 ± 480	39.3 ± 1.0	Mixed	70 (53.4)
EXPOsOMICS: Rhea, Environage and Piccolipiu	324	297 (91.7)	22 (6.8)	3368 ± 437	39.4 ± 1.2	European	169 (52.1)
GECKO	255	206 (80.8)	46 (18.0)	3543 ± 533	39.7 ± 1.3	European	136 (53.3)
Gen3G	162	145 (89.5)	15 (9.3)	3408 ± 431	39.5 ± 1.1	European	74 (45.7)
Generation R	717	589 (82.1)	122 (17.0)	3572 ± 465	40.2 ± 1.1	European	372 (51.9)
GOYA ^b	947	649 (68.5)	294 (31.0)	3750 ± 501	40.4 ± 1.3	European	483 (51.0)
Healthy Start: African American	77	-	-	3059 ± 358	38.9 ± 1.3	African American	42 (54.5)
Healthy Start: Hispanic	115	-	-	3322 ± 395	39.1 ± 1.1	Hispanic	55 (47.8)
Healthy Start: Caucasian	240	220 (91.7)	14 (5.8)	3325 ± 425	39.3 ± 1.1	European	125 (52.1)
INMA	166	-	-	3297 ± 400	39.9 ± 1.2	European	82 (49.4)
IOW F2	118	97 (82.2)	17 (14.4)	3432 ± 525	39.7 ± 1.6	European	59 (50.0)
MoBa1	1066	795 (74.6)	251 (23.5)	3644 ± 544	39.5 ± 1.6	European	568 (53.3)
MoBa2	587	435 (74.1)	146 (24.9)	3701 ± 487	40.1 ± 1.2	European	329 (56.0)
MoBa3	205	153 (74.6)	51 (24.9)	3706 ± 491	39.8 ± 1.2	European	106 (51.7)
NCL ^a	792	592 (74.7)	192 (24.2)	3671 ± 506	40.0 ± 1.3	European	453 (57.2)
NEST: African American	99	-	-	3197 ± 534	39.3 ± 1.2	African American	47 (47.5)
NEST: Caucasian	111	94 (84.7)	13 (11.7)	3446 ± 471	39.5 ± 1.2	European	50 (45.0)
NHBCS	96	84 (87.5)	12 (12.5)	3509 ± 453	39.6 ± 1.1	European	53 (55.2)
PREDO	540	428 (79.3)	99 (18.3)	3572 ± 478	40.1 ± 1.2	European	264 (48.8)
PRISM	138	-	-	3385 ± 441	39.5 ± 1.1	Mixed	76 (55.1)
PROGRESS	143	-	-	3124 ± 387	38.6 ± 1.1	Hispanic	77 (53.8)
RICHs	89	52 (58.4)	23 (25.8)	3335 ± 734	38.9 ± 1.2	European	35 (39.3)
Project Viva	329	263 (79.9)	64 (19.5)	3623 ± 473	40.0 ± 1.2	European	168 (51.1)
Total N	8825	6377	1593				

Results are presented as mean ± SD or N (%). Normal birthweight: 2500–4000 g, high birthweight: >4000 g, low birthweight: <2500 g. Studies with mixed ethnicities analysed all participants together with adjustment for ethnicities. g: grams, wk: weeks, y: years. Full study names can be found in study-specific Supplementary Methods. For some studies the sample size for defining normal/high BW was too small.

^aCBC, CHS and NCL used heel prick blood spot samples instead of cord blood.

^bGOYA is a case-cohort study (cases are mothers with BMI>32 and controls are mothers randomly sampled from the underlying study population in which the cases were identified), in analyses where we included a random sample with a normal BMI distribution results were essentially the same as in the main analyses.

the two African cohorts revealed that 94.9% and 74.0% of the 914 CpGs showed consistent direction of association, with Pearson correlation coefficients for point estimates of 0.82 and 0.48, respectively (Supplementary Data 3). In leave-one-out analyses, in which we reran the main meta-analysis repeatedly with one of the 24 studies removed each time, there was no strong evidence that any one study influenced findings consistently across the 914 differentially methylated CpGs that passed Bonferroni correction and for which between-study heterogeneity had an $I^2 \leq 50\%$. For 139/914 CpGs (15.2%) the difference in mean birthweight for a 10% greater methylation at that site varied by $\geq 20\%$ with removal of a study, but the study resulting in the change was different for different CpGs. Supplementary Fig. 3.1–3.20 show the results for a random 10 plots where removal of one study changed the result by 20% or more and a random 10 where this was not the case; full results are available on request from the authors. Findings were broadly consistent when birthweight was categorised to high (>4000 g, $n = 1593$) versus normal (2500–4000 g, $n = 6377$) (Supplementary Data 4, yellow track (5) in Fig. 4) and when we did not exclude neonates born preterm or to women with pre-eclampsia or diabetes (Supplementary Fig. 4 and Supplementary Data 5A and 5C, and red track (3) in Fig. 4). Without these exclusions, we were able to examine associations with low (<2500 g, $n = 178$) versus normal (2500–4000 g, $n = 4197$) birthweight, though statistical power was

still limited. Four CpGs were associated with low versus normal birthweight (Bonferroni-corrected threshold), none of which overlapped with the 914 CpGs from the main analysis (Supplementary Data 5B, purple track (4) in Fig. 4). We identified that 161 of the 914 differentially methylated CpGs potentially contained a single-nucleotide polymorphism (SNP) at cytosine or guanine positions (i.e. polymorphic CpGs; Supplementary Data 6). Polymorphic CpGs may affect probe binding and hence measured DNA methylation levels^{26,27}. We used one of the largest studies (ALSPAC; $n = 633$) to explore this. We found no indication of bimodal distributions for any of the 161 CpGs suggesting SNPs had not markedly affected methylation measurements at these sites (dip test p -values: 0.299–1.00)^{28–30}.

Analyses at older ages. We took the 914 neonatal blood CpGs that were associated with birthweight at Bonferroni-corrected statistical significance and with $I^2 \leq 50\%$ and examined their associations with birthweight when measured in blood taken in childhood (2–13 years; $n = 2756$ from 10 studies), adolescence (16–18 years; $n = 2906$ from six studies) and adulthood (30–45 years; $n = 1616$ from three studies). Only participants from ALSPAC, CHAMACOS and Generation R had also contributed to the main neonatal blood EWAS. In childhood, adolescence and adulthood, we observed 87, 49 and 42 of the 914 CpGs to be nominally associated with birthweight ($p < 0.05$).




Fig. 2 Design of the study. Schematic representation of the main meta-analysis, secondary meta-analyses, follow-up analyses and exploration of persistence at older ages. *We removed multiple births from all analyses and excluded preterm births (<37 weeks) and offspring of mothers with pre-eclampsia or diabetes (three major pathological causes of differences). **For sufficient power in the low vs normal BW analyses, we only included nine studies with >10 low birthweight cases




Fig. 3 Volcano plot showing the direction of associations of DNA methylation with birthweight in 8825 neonates from 24 studies. The X-axis represents the difference in birthweight in grams per 10% methylation difference, the Y-axis represents the $-\log_{10}(P)$. The red line shows the Bonferroni-corrected significance threshold for multiple testing ($p < 1.06 \times 10^{-7}$). Highlighted in orange are the 914 CpGs with $p < 1.06 \times 10^{-7}$ and $I^2 \leq 50\%$ and highlighted in blue are the 115 CpGs with $p < 1.06 \times 10^{-7}$ and $I^2 > 50\%$

All these CpGs showed consistent directions of association. Ten CpGs showed differential methylation across all four age periods. However, only a minority survived Bonferroni correction for 914 tests ($p < 5.5 \times 10^{-5}$): 12 (1.3%), 1 (0.1%) and 0 CpGs in childhood, adolescence and adulthood, respectively (Supplementary Data 7; the 12 CpGs that persisted in childhood are presented in the green track (6) in Fig. 4). Of the 914 CpGs, 50, 52 and 49% showed consistency in direction of association in childhood, adolescence and adulthood, but correlations of the associations of DNA methylation and birthweight between methylation measured in infancy and that measured in childhood, adolescence and adulthood were weak (Pearson correlation coefficients: 0.15, 0.06 and 0.02, respectively).

Intrauterine factors. We observed enrichment of previously published maternal smoking-related CpGs in the birthweight-associated CpGs¹⁴ (55/914 (6.0%) $p_{\text{enrichment}} = 6.12 \times 10^{-74}$, of which cg00253658 and cg26681628 also showed persistent methylation

differences in the look-up in childhood). We additionally found enrichment of maternal BMI-related CpGs in the list of birthweight-related CpGs¹⁵ (3/914 (0.3%) $p_{\text{enrichment}} = 1.13 \times 10^{-3}$). All directions of association were consistent with the birthweight-lowering influence of maternal smoking or the positive association of maternal BMI with birthweight (Supplementary Data 8). We did not find evidence for overlap with plasma folate³¹. For famine, we were unable to explore overlap with DNA methylation at the Bonferroni-significant level as the previous EWAS of famine only reported results that reached a FDR level of statistical significance³². In additional analyses for overlap between all FDR hits from the birthweight EWAS with those FDR hits presented in the smoking, maternal BMI, folate and famine EWAS, we found an overlap of 430/8170 CpGs (5.3%, $p_{\text{enrichment}} = 7.38 \times 10^{-132}$) for smoking, 584/8170 CpGs (7.1%, $p_{\text{enrichment}} = 3.34 \times 10^{-62}$) for maternal BMI and 14/8170 (0.2%, $p_{\text{enrichment}} = 0.02$) for folate. For famine we did not observe overlap.




Fig. 4 Circos plot showing the (Bonferroni-corrected $p < 1.06 \times 10^{-7}$) results for associations of DNA methylation with birthweight. Results are presented as CpG-specific associations ($-\log_{10}(P)$, each dot represents a CpG) by genomic position, per chromosome. From outer to inner track: [1, orange] Main analysis results for associations between DNA methylation and birthweight as a continuous measure ($n = 8825$), [2, blue] Results from participants from European ethnicity only, DNA methylation and birthweight as a continuous measure ($n = 6023$), [3, red] Results from analysis without exclusion for preterm births, pre-eclampsia and maternal diabetes, DNA methylation and birthweight as a continuous measure $n = 5414$), [4, purple] Results from logistic regression analysis without exclusion for preterm births, pre-eclampsia and maternal diabetes, for low ($n = 178$) vs normal ($n = 4197$) birthweight, [5, yellow] Results from logistic regression analysis for associations between DNA methylation and high ($n = 1590$) vs normal ($n = 6114$) birthweight, [6, green] Results from look-up analysis in methylation samples taken during childhood and its association with birthweight as a continuous measure ($n = 2756$). Track 1: highlighted in red are 115 CpGs with $I^2 > 50\%$. Tracks 2–6: highlighted in red are CpGs that were not found in the 914 main meta-analysis hits (though note differences in sample size and hence statistical power for different analyses presented in the different tracks)

Metastable epialleles and imprinted genes. We tested the birthweight-associated CpGs for enrichment of metastable epialleles (loci for which the methylation state is established in the periconceptional period^{33,34}). We additionally tested for enrichment of CpGs annotated to imprinted genes (loci that depend on the maintenance of parental-origin-specific methylation marks in the pre-implantation embryo, some of which are known to regulate fetal growth^{35,36}). We did not find evidence of enrichment for metastable epialleles (3/1936 metastable epialleles overlap a birthweight-associated CpG), imprinting control regions (0/741) or imprinted gene transcription start sites (5/1728) (Supplementary Data 9).

Comparison with GWAS for birthweight. To compare these EWAS results to those from genetic studies, we used the 60 recently published fetal SNPs associated with birthweight in a GWAS meta-analysis of 153,781 newborns³⁷ and mapped the CpG sites identified in the EWAS to these SNPs to seek evidence of co-localisation of

genetic and epigenetic variation (Supplementary Data 10). We repeated this for the 10 recently published maternal SNPs associated with birthweight in a GWAS meta-analysis of 86,577 women³⁸ (Supplementary Data 11). We observed that one or more of the 914 birthweight-associated CpGs were within ± 2 Mb of 34/60 fetal and all 10 maternal birthweight-associated SNPs. Of the 34 fetal SNPs, three were located in the same gene as the CpG, as was one of the ten maternal SNPs. Ten fetal and four maternal SNPs were within 100 kb of identified CpGs. In a look-up of the fetal and maternal SNPs from GWAS of birthweight in an online cord blood methylation quantitative trait loci (mQTL) database (mqtlb.org³⁹), 35 fetal and four maternal SNPs affected methylation at some CpG(s), but none at the 914 birthweight-associated CpGs specifically.

Functional analyses. We compared the 914 birthweight-related CpGs with a recently published list of 18,881 expression quantitative trait methylation sites (cis-eQTMs, ± 250 kb around

the transcription start site), CpG sites known to correlate with gene expression, from whole blood samples of 2101 Dutch adult individuals. We found that 82 of the 914 birthweight-associated CpGs were associated with gene expression of 98 probes (cis-eQTM)⁴⁰ ($p_{\text{enrichment}} < 1.73 \times 10^{-11}$, Supplementary Data 12). Additionally, in 112 Spanish 4-year-olds⁴¹, we observed that 19 CpGs were inversely associated with whole blood mRNA gene expression and four CpGs were positively associated with gene expression (FDR<0.05, Supplementary Data 13). Of these 23 CpGs, 13 were also found in the publicly available cis-eQTM list⁴⁰. In 84 Gambian children (age 2 years)⁴², we found two CpGs that were inversely associated with whole blood mRNA gene expression, but neither were found in the Spanish results or the publicly available cis-eQTM list. The 914 birthweight-associated CpGs showed no functional enrichment of Gene Ontology (GO) terms or Kyoto Encyclopedia of Genes and Genomes (KEGG) terms (FDR<0.05).

Mendelian randomization. We aimed to explore causality using MR analysis, in which genetic variants associated with methylation levels (methylation quantitative trait loci (mQTLs)) are used as instrumental variables to appraise causality. For 788 (86%) of the 914 birthweight-associated CpGs, no mQTLs were identified in a publicly available mQTL database³⁹. For 108 (86%) of the remaining 126 CpGs, only one mQTL was identified and for the remainder none had more than four mQTLs (Supplementary Data 14 provides a complete list of all mQTLs identified for these 126 CpGs). Many of the currently available methods that can be used as sensitivity analyses to explore whether MR results are biased by horizontal pleiotropy (a single mQTL influencing multiple traits) require more than one genetic instrument (here mQTLs) and even with two or three this can be difficult to interpret⁴³. Having determined that it was not possible to undertake MR analyses of 86% of the birthweight-related differentially methylated CpGs (because we did not identify any mQTLs), and for the majority of the remaining CpGs we would not have been reliably able to distinguish causality from horizontal pleiotropy (because only one mQTL could be identified), we decided not to pursue MR analyses further.

Discussion

This large-scale meta-analysis shows that birthweight is associated with widespread differences in DNA methylation. We observed some enrichment of birthweight-associated CpGs among sites that have previously been linked to smoking during pregnancy¹⁴ and pre-pregnancy BMI¹⁵, consistent with the hypothesis that epigenetic pathways may underlie the observational associations of those prenatal exposures with birthweight^{21,44,45}. However, the actual overlap in this analysis was modest, likely explained by the adjustments for maternal smoking and BMI in the EWAS analyses. The overlap that we observed with pregnancy smoking-related CpGs may reflect the possibility that smoking-related CpGs capture smoking better than self-report^{46,47}, in line with expectations of pregnant women underreporting their smoking behaviour. Adjustment for maternal smoking and BMI may have masked a greater level of overlap between our results and EWAS of these two maternal exposures. The fact that we find an association of DNA methylation across the genome with birthweight provides some support for our conceptual framework shown in Fig. 1. However, we acknowledge that the associations that we have observed may also be explained by causal effects of maternal pregnancy exposures on both DNA methylation and fetal growth, as well as subtle inflammatory responses in cell-type proportions associated with maternal smoking that might not have been completely captured with the currently available cell type estimation methods.

The differential methylation associated with birthweight in neonates persisted only minimally across childhood and into adulthood.

Larger (preferably longitudinal) studies are needed to explore persistent differential methylation in more detail and with better power at older ages. It is possible that inclusion of the Gambia study in the childhood EWAS (which was the only non-European study in these analyses and was not included in the main meta-analyses with neonatal blood) might have impacted these results, although this study made up just 7% of the total child follow-up sample. A rapid attenuation of differential methylation in relation to birthweight in the first years after birth has previously been reported¹⁹, but our sample size for these analyses may have been too small to detect persistence. This rapid decrease, if real, may indicate a reduction in the dose of the child's exposure to maternal factors such as smoking once the offspring is delivered, with that reduction continuing as the child ages. Persistence of birthweight-related differential DNA methylation may not necessarily be a prerequisite for long-term effects, as transient differential methylation in early life may cause lasting functional alterations in organ structure and function that predispose to later adverse health effects.

Methylation is known to be associated with gene expression⁴⁸. However, we found no consistent associations between birthweight-related methylation and gene expression in two childhood studies. This could be due to the relatively small sample sizes, differences in ethnicities, age, or platforms to measure gene expression. The use of blood, which is likely only a possible surrogate tissue for fetal growth phenotypes, for gene expression analysis might also explain the lack of findings. We did find multiple cis-eQTMs among the birthweight-related CpGs at which methylation was related to gene expression in blood when using a publicly available database from a larger adult sample⁴⁰, providing some evidence that birthweight-related differentially methylated CpGs may be associated with gene expression. These initial in silico association analyses need further exploration to establish any underlying causal mechanisms.

In observational studies, birthweight has repeatedly been associated with a range of later-life diseases. Change in DNA methylation has been hypothesized as a potential mechanism linking early exposures, birthweight and later health (Fig. 1). We originally aimed to explore this using MR analysis. For the vast majority of the birthweight-associated CpGs, no genetic instrumental variables were available. For the remaining 126 CpGs, only one mQTL was available, which would make it impossible to disentangle causality from horizontal pleiotropy. To ensure a strong basis for future MR analyses on this topic, there is a clear need for a more extensive mQTL resource.

Strengths of this study are its large sample size and the extensive analyses that we have undertaken. In a post hoc power calculation based on the sample size of 8825 with a weighted mean birthweight of 3560 g (weighted mean standard deviation (SD): 483 g) and with an alpha set at the Bonferroni-corrected level of $P < 1.06 \times 10^{-7}$ we had 80% power, with a two-sided test, to detect a minimum difference of 0.13 SD (63 g) in birthweight for each SD increase in methylation. The difference in methylation corresponding to a 1 SD increase differs per CpG, as it depends on the distribution of the methylation values. We acknowledge that smaller differences which might be clinically or biologically relevant may not have been identified in the current analysis. Nonetheless, to our knowledge this analysis has brought together all studies currently available with relevant data and is the largest published study of this association. DNA methylation patterns in neonatal blood, whilst easily accessible in large numbers, may not reflect the key tissue of importance in relation to birthweight. DNA methylation and gene expression in placental tissue may be important targets for future studies. DNA methylation varies between leucocyte subtypes⁴⁹ and we used an adult whole blood reference to correct for this in the main analyses^{23,24}, as the study-specific analyses were completed before the widespread availability of specific cord blood reference datasets^{50,51}. However, we observed very similar findings in two studies

(Generation R and GECKO) when we compared the results with those using one of the currently available cord blood references⁵⁰. Although we adjusted for potential major confounders that may affect both methylation and fetal growth, we acknowledge that the main results cannot ascertain causality. That is, whilst we have hypothesised that variation in fetal DNA methylation influences fetal growth and hence birthweight, and undertaken the analyses accordingly, we cannot exclude the possibility that differences in neonatal blood DNA methylation are caused by variation in fetal growth itself, or that the association is confounded by factors, including maternal smoking and BMI, that independently influence both fetal growth and DNA methylation (as suggested in Fig. 1). The 450k array that was used to measure genome-wide DNA methylation only covers 1.7% of the total number of CpGs present in the genome and specifically targets CpGs in promoter regions and gene bodies⁵². We removed the CpGs that were flagged as potentially cross-reactive, as the measured methylation levels may represent methylation at either of the potential loci. Also, although we did not find evidence for polymorphic effects for the 161 potentially polymorphic CpGs in ALSPAC, we cannot completely exclude these potential polymorphic effects in the meta-analysed results. The majority of participants were of European ethnicity and when analyses were restricted to those of European ethnicity the results were essentially identical to those with all studies included. Direct comparisons of the main analysis with analyses in those of Hispanic or of African ethnicity for the 914 hits suggested strong correlations with Hispanic but weaker with African ethnicity. However, these results need to be treated with caution. First, we had very few studies of Hispanic and African populations. Second, we only compared the initial hits from the main meta-analysis with all ethnicities included. A detailed exploration of ethnic differences would require similar large samples for each ethnic group and within ethnic EWAS, which is beyond the scope of the data currently available.

Neonatal blood DNA methylation at many sites across the genome is associated with birthweight. Further research is required to determine if these are causal and if so whether they mediate any long-term effect of intrauterine exposures on future health.

Methods

Participants. In the main EWAS meta-analysis we explored associations of neonatal blood DNA methylation with birthweight using data from 8825 neonates from 24 studies in the PACE Consortium⁵³ (Table 1). We removed multiple births from all analyses and excluded preterm births (<37 weeks) and offspring of mothers with pre-eclampsia or diabetes (three major pathological causes of differences in fetal growth). In follow-up analyses, we explored whether any sites found in the main analysis were discernible in relation to birthweight when examined in DNA from blood drawn during childhood (2–13 years; 2756 children from 10 studies), adolescence (16–18 years; 2906 adolescents from six studies) or adulthood (30–45 years; 1616 adults from three studies), see Supplementary Data 1B. Informed consent was obtained from all participants, and all studies received approval from local ethics committees. Study-specific methods and ethical approval statements are provided in Supplementary Methods.

Birthweight, DNA methylation and covariates. Our primary outcome was birthweight on a continuous scale (grams), adjusted for gestational age, and measured immediately after birth or retrospectively reported by mothers in questionnaires. In secondary analyses, we categorised and compared associations with high (>4000 g, $n = 1593$) versus normal (2500–4000 g, $n = 6377$) birthweight. We also explored all associations with (continuous and categorical) birthweight in analyses that did not exclude women with pre-eclampsia, diabetes or preterm delivery, which also resulted in enough cases to explore low (<2500 g, $n = 178$) versus normal (2500–4000 g, $n = 4197$) birthweight (Supplementary Data 1C shows the characteristics of participants). Primary, secondary and follow-up analyses are outlined in the study design in Fig. 2. DNA methylation was measured in neonatal blood samples using the Illumina Infinium® HumanMethylation450 BeadChip assay. All participants had cord blood samples except for three studies with heel stick blood spots ($n = 1254$ [14.2%]). After study-specific laboratory analyses, quality control, normalisation, and removal of control probes ($n = 65$) and probes that mapped to the X ($n = 11,232$) and Y ($n = 370$) chromosomes, we included 473,864 CpGs. DNA methylation is expressed as the proportion of cells in which the DNA was methylated at a specific site and hence takes values from zero to one. We converted this to a percentage and present differences in

mean birthweight per 10% higher DNA methylation level at each CpG. All analyses were adjusted for gestational age at delivery, child sex, maternal age at delivery, parity (0/≥1), smoking during pregnancy (no smoking/stopped in early pregnancy/smoking throughout pregnancy), pre-pregnancy BMI, socio-economic position, technical variation, and estimated white blood cell proportions (B-cells, CD8+ T-cells, CD4+ T-cells, granulocytes, NK-cells and monocytes)^{23–25}. In studies with participants from multiple ethnic groups, each group was analysed separately and results were added to the meta-analyses as separate studies. Further details are provided in the study-specific Supplementary Methods.

Statistical methods. Robust linear (birthweight as a continuous outcome) or logit (binary birthweight outcomes) regression EWAS were undertaken within each study according to a pre-specified analysis plan. Quality control, normalisation and regression analyses were conducted independently by each study. After confirming comparability of study-specific summary statistics⁵⁴, we combined results using a fixed effects inverse variance weighted meta-analysis⁵⁵. The meta-analysis was done independently by two study groups and the results were compared in order to minimise the likelihood of human error. We show (two-sided) results after correcting for multiple testing using both the FDR<0.05⁵⁶ and the Bonferroni correction ($p < 1.06 \times 10^{-7}$). We completed follow-up analyses for differentially methylated CpGs that reached the Bonferroni-adjusted threshold and did not show large between-study heterogeneity⁵⁷ ($I^2 \leq 50\%$). We annotated the nearest gene for each CpG using the UCSC Genome Browser build hg19^{58,59}. We explored whether between-study heterogeneity might be explained by differences in ethnicity between studies, by repeating the meta-analysis including only participants of European ethnicity, which was by far the largest ethnic subgroup ($n = 6023$ from 17 studies) (Fig. 2). Ethnicity was defined using maternal or self-report, unless specified otherwise in study-specific Supplementary Methods. We also did meta-analyses only including the Hispanic studies and only including the African American studies and present those results for illustrative purposes only, given the much smaller sample size. All analyses were performed using R⁶⁰, except for the meta-analysis which was performed using METAL⁵⁵. We removed CpGs that co-hybridised to alternate sequences (i.e. cross-reactive sites), because we cannot distinguish whether the differential methylation is at the locus that we have reported or at the one that the probe cross-reacts with. We compared the birthweight-related CpGs to lists of CpGs that are potentially influenced by a SNP (polymorphic sites)^{26,27}. For these CpGs, we determined if DNA methylation levels were influenced by nearby SNPs, by assessing whether their distributions deviated from unimodality using Hartigan's dip test^{28,29} and visual inspection of density plots in $n = 742$ cord blood samples in the ALSPAC study.

Analyses at older ages. Analyses of the associations with DNA methylation in blood collected in childhood, adolescence and adulthood followed the same covariable adjustment and methods as for the main analyses ($p < 5.5 \times 10^{-5}$ for 914 tests). All participants and studies in these analyses at older ages had not been included in the main meta-analysis in neonatal blood, except for ALSPAC ($n = 633$ in neonatal analyses, $n = 605$ in childhood and $n = 526$ in adolescence), CHA-MACOS ($n = 283$ in neonatal analyses and $n = 191$ in childhood) and Generation R ($n = 717$ in neonatal analyses and $n = 372$ in childhood). Characteristics are shown in study-specific Supplementary Methods and Supplementary Data 1B.

Intrauterine factors. We used a hypergeometric test to explore the extent to which any of the birthweight-related CpGs overlapped with those previously associated with intrauterine exposure to smoking¹⁴ ($n = 568$ CpGs), BMI¹⁵ ($n = 104$ CpGs) and plasma folate³¹ ($n = 48$ CpGs), using the same (Bonferroni-corrected) cut-off for statistical significance. No CpGs reached the Bonferroni-corrected cut-off for famine³². We additionally appraised this overlap using the FDR<0.05 cut-off for all traits ($n = 8170$ birthweight-related CpGs, $n = 6703$ smoking-related CpGs, $n = 16,067$ BMI-related CpGs, $n = 443$ folate-related CpGs, $n = 7$ famine-related CpGs). These FDR results were available from the publications for smoking, folate and famine, and we obtained them from the corresponding author for BMI.

Metastable epialleles and imprinted genes. We tested the birthweight-associated CpGs for enrichment of metastable epialleles and CpGs associated with imprinted genes. The metastable epialleles were derived from a recently published study that identified 1936 putative metastable epialleles³⁴. For imprinted genes, we first identified a set of CpGs falling within a curated set of imprinting control regions; differentially methylated regions controlling the parental-specific expression of one or more imprinted genes³⁶. Second, we extracted the set of imprinting control region controlled genes from the above source and identified all 450k CpGs within ± 10 kbp of the gene transcription start site, including all known alternative TSS identified in grch37.ensembl.org using biomaRt^{61,62}.

Comparison with GWAS for birthweight. We compared the birthweight-associated CpGs with the 60 SNPs from the most recent GWAS meta-analyses of fetal genotype associations with birthweight in >150,000 newborns³⁷ and with the 10 SNPs from the most recent GWAS meta-analysis of maternal genotype associations with birthweight in >86,000 women³⁸. With this comparison we checked if the EWAS top hits were located within a 4 Mb window (± 2 Mb)

surrounding these SNPs. We additionally checked whether SNPs and CpGs were located in the same gene.

Functional analyses. To explore the association of methylation with gene expression, we compared birthweight-related CpGs with a recently published list of 18,881 cis-eQTM from whole blood samples of 2101 Dutch adult individuals⁴⁰. With a hypergeometric test, we calculated enrichment of cis-eQTMs in the list of birthweight-associated CpGs. We further explored methylation of birthweight-associated CpGs in relation to whole blood mRNA gene expression (transcript levels) within a 500 kb region of the CpGs (± 250 kb, $\text{FDR} < 0.05$) in 112 Spanish 4-year-olds⁴¹ and 84 Gambian 2-year-olds⁴² (Supplementary Methods). To better understand the potential mechanisms linking DNA methylation and birthweight, we explored the potential functions of the birthweight-associated CpGs using GO and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. We used the missMethyl R package⁶³, which enabled us to correct for the number of probes per gene on the 450k array, based on the November 2018 version of the GO and KEGG source databases. To filter out the large, general pathways we set the number of genes for each gene set between 15 and 1000, respectively. We calculated FDR at 5% corrected *P*-values for enrichment.

Mendelian randomization. MR uses genetic variants as instrumental variables to study the causal effect of exposures on outcomes^{64,65}. We aimed to use two-sample MR^{22,66} to explore (a) evidence of a causal association of methylation levels at the identified CpGs with birthweight and (b) evidence of a causal association of these CpGs with later-life health outcomes (i.e. to explore our hypothesised causal mechanisms shown in Fig. 1). We did this by first searching a publicly available mQTL database³⁹ to identify cis-mQTLs within 1 Mb of each of the Bonferroni-corrected, with $I^2 \leq 50\%$, birthweight-related differentially methylated CpGs. These mQTLs could then be used as genetic instrumental variables for methylation levels of the birthweight-related CpGs. We then aimed to determine the association of these mQTLs with birthweight and later-life health outcomes from publicly available summary GWAS results⁶⁶.

Reporting summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this article.

Data availability

All relevant data supporting the key findings of this study are available within the article and its Supplementary Information files or from the corresponding authors upon reasonable request. All summary statistics from this EWAS meta-analysis are available via doi: 10.5281/zenodo.2222287. A reporting summary for this Article is available as a Supplementary Information file.

Code availability

The code used for this EWAS meta-analysis is available from the authors upon request.

Received: 30 April 2018 Accepted: 18 February 2019

Published online: 23 April 2019

References

1. Tyrrell, J. et al. Genetic evidence for causal relationships between maternal obesity-related traits and birth weight. *JAMA* **315**, 1129 (2016).
2. Tyrrell, J. et al. Genetic variation in the 15q25 nicotinic acetylcholine receptor gene cluster (CHRNA5-CHRNA3-CHRNA4) interacts with maternal self-reported smoking status during pregnancy to influence birth weight. *Hum. Mol. Genet.* **21**, 5344–5358 (2012).
3. Bakker, R., Steegers, E. A. P., Hofman, A. & Jaddoe, V. W. V. Blood pressure in different gestational trimesters, fetal growth, and the risk of adverse birth outcomes: the generation R study. *Am. J. Epidemiol.* **174**, 797–806 (2011).
4. Lawlor, D. A. et al. Association of existing diabetes, gestational diabetes and glycosuria in pregnancy with macrosomia and offspring body mass index, waist and fat mass in later childhood: Findings from a prospective pregnancy cohort. *Diabetologia* **53**, 89–97 (2010).
5. van Uiter, E. M. & Steegers-Theunissen, R. P. M. Influence of maternal folate status on human fetal growth parameters. *Mol. Nutr. Food. Res.* **57**, 582–595 (2013).
6. Painter, R. C., Roseboom, T. J. & Bleker, O. P. Prenatal exposure to the Dutch famine and disease in later life: an overview. *Reprod. Toxicol.* **20**, 345–352 (2005).
7. Whincup, P. H. et al. Birth weight and risk of type 2 diabetes a systematic review. *JAMA* **300**, 2886–2897 (2008).
8. Lawlor, D. A., Ronalds, G., Clark, H., Davey Smith, G. & Leon, D. A. Birth weight is inversely associated with incident coronary heart disease and stroke among individuals born in the 1950s: findings from the Aberdeen children of the 1950s prospective cohort study. *Circulation* **112**, 1414–1418 (2005).
9. O'Donnell, K. J. & Meaney, M. J. Fetal origins of mental health: the developmental origins of health and disease hypothesis. *Am. J. Psychiatry* **174**, 319–328 (2017).
10. McCormack, V. A., Silva, I. D. S., Koupil, I., Leon, D. A. & Lithell, H. O. Birth characteristics and adult cancer incidence: Swedish cohort of over 11,000 men and women. *Int. J. Cancer* **115**, 611–617 (2005).
11. Risnes, K. R. et al. Birthweight and mortality in adulthood: a systematic review and meta-analysis. *Int. J. Epidemiol.* **40**, 647–661 (2011).
12. Freathy, R. M. Can genetic evidence help us to understand the fetal origins of type 2 diabetes? *Diabetologia* **59**, 1850–1854 (2016).
13. Hanson, M. Birth weight and the fetal origins of adult disease. *Pediatr. Res.* **52**, 473–474 (2002).
14. Joubert, B. R. et al. DNA methylation in newborns and maternal smoking in pregnancy: genome-wide consortium meta-analysis. *Am. J. Hum. Genet.* **98**, 680–696 (2016).
15. Sharp, G. C. et al. Maternal BMI at the start of pregnancy and offspring epigenome-wide DNA methylation: findings from the pregnancy and childhood epigenetics (PACE) consortium. *Hum. Mol. Genet.* **26**, 4067–4085 (2017).
16. Gruzieva, O. et al. Epigenome-wide meta-analysis of methylation in children related to prenatal NO₂ air pollution exposure. *Environ. Health Perspect.* **125**, 104–110 (2017).
17. Adkins, R. M., Tylavsky, F. A. & Krushkal, J. Newborn umbilical cord blood DNA methylation and gene expression levels exhibit limited association with birth weight. *Chem. Biodivers.* **9**, 888–899 (2012).
18. Engel, S. M. et al. Neonatal genome-wide methylation patterns in relation to birth weight in the Norwegian Mother and Child Cohort. *Am. J. Epidemiol.* **179**, 834–842 (2014).
19. Simpkin, A. J. et al. Longitudinal analysis of DNA methylation associated with birth weight and gestational age. *Hum. Mol. Genet.* **24**, 3752–3763 (2015).
20. Agha, G. et al. Birth weight-for-gestational age is associated with DNA methylation at birth and in childhood. *Clin. Epigenetics* **8**, 1–12 (2016).
21. Lawlor, D. A., Relton, C., Sattar, N. & Nelson, S. M. Maternal adiposity—a determinant of perinatal and offspring outcomes? *Nat. Rev. Endocrinol.* **8**, 679–688 (2012).
22. Lawlor, D. A. Commentary: Two-sample Mendelian randomization: opportunities and challenges. *Int. J. Epidemiol.* **45**, 908–915 (2016).
23. Houseman, E. A. et al. DNA methylation arrays as surrogate measures of cell mixture distribution. *BMC Bioinformatics* **13**, 1–16 (2012).
24. Reinius, L. E. et al. Differential DNA methylation in purified human blood cells: implications for cell lineage and studies on disease susceptibility. *PLoS. ONE* **7**, e41361 (2012).
25. Aryee, M. J. et al. Minfi: A flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. *Bioinformatics* **30**, 1363–1369 (2014).
26. Chen, Y. A. et al. Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium HumanMethylation450 microarray. *Epigenetics* **8**, 203–209 (2013).
27. Naem, H. et al. Reducing the risk of false discovery enabling identification of biologically significant genome-wide methylation status using the HumanMethylation450 array. *BMC Genomics* **15**, 51 (2014).
28. Hartigan, J. & Hartigan, P. The dip test of unimodality. *Ann. Stat.* **13**, 70–84 (1985).
29. Maechler, M. Hartigan's dip test statistic for unimodality - corrected. R package. (2015).
30. Relton, C. L. et al. Data resource profile: accessible resource for integrated epigenomic studies (ARIES). *Int. J. Epidemiol.* **44**, 1181–1190 (2015).
31. Joubert, B. R. et al. Maternal plasma folate impacts differential DNA methylation in an epigenome-wide meta-analysis of newborns. *Nat. Commun.* **7**, 10577 (2016).
32. Tobi, E. W. et al. Early gestation as the critical time-window for changes in the prenatal environment to affect the adult human blood methylome. *Int. J. Epidemiol.* **44**, 1211–1223 (2015).
33. Rakan, V. K., Blewitt, M. E., Druker, R., Preis, J. I. & Whitelaw, E. Metastable epialleles in mammals. *Trends Genet.* **18**, 348–351 (2002).
34. Van Baak, T. E. et al. Epigenetic supersimilarity of monozygotic twin pairs. *Genome. Biol.* **19**, 2 (2018).
35. Moore, G. E. et al. The role and interaction of imprinted genes in human fetal growth. *Philos. Trans. R. Soc. Lond. B. Biol. Sci.* **370**, 20140074 (2015).
36. Monk, D. et al. Recommendations for a nomenclature system for reporting methylation aberrations in imprinted domains. *Epigenetics* **1–5** <https://doi.org/10.1080/15592294.2016.1264561> (2016).
37. Horikoshi, M. et al. Genome-wide associations for birth weight and correlations with adult disease. *Nature* **4**, 1–20 (2016).
38. Beaumont, R. N. et al. Genome-wide association study of offspring birth weight in 86 577 women identifies five novel loci and highlights maternal genetic effects that are independent of fetal genetics. *Hum. Mol. Genet.* **27**, 742–756 (2018).

39. Gaunt, T. R. et al. Systematic identification of genetic influences on methylation across the human life course. *Genome. Biol.* **17**, 1–14 (2016).
40. Bonder, M. J. et al. Disease variants alter transcription factor levels and methylation of their binding sites. *Nat. Genet.* **49**, 131–138 (2016).
41. Guxens, M. et al. Cohort profile: the INMA—INfancia y Medio Ambiente—(environment and childhood) project. *Int. J. Epidemiol.* **41**, 930–940 (2012).
42. Moore, S. E. et al. A randomized trial to investigate the effects of pre-natal and infant nutritional supplementation on infant immune development in rural Gambia: the ENID trial: early nutrition and immune development. *BMC Pregnancy Childbirth* **12**, 1–8 (2012).
43. Hemani, G., Bowden, J. & Davey Smith, G. Evaluating the potential role of pleiotropy in Mendelian randomization studies. *Hum. Mol. Genet.* **27**, R195–R208 (2018).
44. Richmond, R. C., Timpson, N. J. & Sørensen, T. I. A. Exploring possible epigenetic mediation of early-life environmental exposures on adiposity and obesity development. *Int. J. Epidemiol.* **44**, 1191–1198 (2015).
45. Küpers, L. K. et al. DNA methylation mediates the effect of maternal smoking during pregnancy on birthweight of the offspring. *Int. J. Epidemiol.* **44**, 1224–1237 (2015).
46. Valeri, L. et al. Misclassified exposure in epigenetic mediation analyses. Does DNA methylation mediate effects of smoking on birthweight? *Epigenomics* **9**, 253–265 (2017).
47. Reese, S. E. et al. DNA methylation score as a biomarker in newborns for sustained maternal smoking during pregnancy. *Env. Heal. Perspect.* <https://doi.org/10.1289/EHP333> (2016).
48. Jaenisch, R. & Bird, A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. *Nat. Genet.* **33**(Suppl), 245–254 (2003).
49. Jaffe, A. E. & Irizarry, R. A. Accounting for cellular heterogeneity is critical in epigenome-wide association studies. *Genome. Biol.* **15**, R31 (2014).
50. Bakulski, K. M. et al. DNA methylation of cord blood cell types: applications for mixed cell birth studies. *Epigenetics* **11**, 354–362 (2016).
51. Gervin, K. et al. Cell type specific DNA methylation in cord blood: a 450K-reference data set and cell count-based validation of estimated cell type composition. *Epigenetics* **11**, 690–698 (2016).
52. Dedeurwaerder, S. et al. Evaluation of the Infinium methylation 450K technology. *Epigenomics* <https://doi.org/10.2217/epi.11.105> (2011).
53. Felix, J. F. et al. Cohort profile: pregnancy and childhood epigenetics (PACE) consortium. *Int. J. Epidemiol.* **16**, 10–14 (2017).
54. van der Most, P. J., Küpers, L. K., Snieder, H. & Nolte, I. QCEWAS: automated quality control of results of epigenome-wide association studies. *Bioinformatics* **33**, 1243–1245 (2017).
55. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* **26**, 2190–2191 (2010).
56. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J. R. Stat. Soc. B* **57**, 289–300 (1995).
57. Higgins, J. P. T. & Thompson, S. G. Quantifying heterogeneity in a meta-analysis. *Stat. Med.* **21**, 1539–1558 (2002).
58. Triche, T. FDb.InfiniumMethylation.hg19: annotation package for Illumina Infinium DNA methylation probes. R package version 2.2.0 (2014).
59. Carlson, M. & Maintainer, B. TxDb.Hsapiens.UCSC.hg19.knownGene: annotation package for TxDb object(s). R package version 3.2.2 (2015).
60. R Core Team. R: A language and environment for statistical computing. (Austria, 2013).
61. Durinck, S. et al. BioMart and Bioconductor: a powerful link between biological databases and microarray data analysis. *Bioinformatics* **21**, 3439–3440 (2005).
62. Durinck, S., Spellman, P. T., Birney, E. & Huber, W. Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt. *Nat. Protoc.* **4**, 1184–1191 (2009).
63. Phipson, B., Maksimovic, J. & Oshlack, A. missMethyl: an R package for analyzing data from Illumina's HumanMethylation450 platform. *Bioinformatics* **32**, 286–288 (2016).
64. Davey Smith, G. & Ebrahim, S. 'Mendelian randomization': Can genetic epidemiology contribute to understanding environmental determinants of disease? *Int. J. Epidemiol.* **32**, 1–22 (2003).
65. Lawlor, D. A., Harbord, R. M., Sterne, J. A. C., Timpson, N. & Davey Smith, G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. *Stat. Med.* **27**, 1133–1163 (2008).
66. Hemani, G. et al. The MR-Base platform supports systematic causal inference across the human phenome. *eLife* **7**, e34408 (2018).

Acknowledgements

For all studies, acknowledgements can be found in Supplementary Information: Supplementary Acknowledgements. For all studies, funding statements can be found in Supplementary Information: Supplementary Funding.

Author contributions

L.K.K., D.A.L., C.L.R., H.S. and J.F.F. conceived and designed the study. Study-specific analyses were completed by G.C.S. (ALSPAC and GOYA), S.K.M. (BAMSE), R.R. (CBC), P.Y. (CHAMACOS), C.V.B. (CHS), K.M.B. (EARLI), A.G. and A.N. (EXPOSOMICS, The Gambia and MoBa3), S.A.S.L. (FLEHSI), L.K.K. (GECKO), C.A. (Gen3G), C.M. (Generation R), J.L. (Glaku), A.P.S. (Healthy Start), L.A.S. (INMA), F.I.R. (IOW F1), J.W.H. (IOW F2), D.A.V.D. P. (Lifelines), C.M.P. (MoBa1), S.E.R. (MoBa2), A.J.W. (NCL), D.D.J. (NEST), M.W. (NFB66 and NFB68), T.M.E. (NHBS and RICH), J.V.D. (NTR), C.J.X. (PIAMA), D.C. (PREDO), A.C.J. (PRISM), A.C.J. (PROGRESS), S.L. (Project Viva), R.C.H. (Raine), V.U. (STOPPA). L.K.K. and C.M. meta-analysed the results. L.K.K., C.M., G.C.S., P.Y., L.A.S., A.G., A.N. and M.J.S. performed follow-up analyses. L.K.K., D.A.L., C.L.R., H.S. and J.F.F. interpreted the results. L.K.K., with input from D.A.L., C.L.R., H.S. and J.F.F., wrote the first draft of the manuscript. All authors (L.K.K., C.M., G.C.S., P.Y., L.A.S., A.G., C.M.P., S.E.R., A.J.W., D.C., A.P.S., A.N., S.L., R.R., C.H., C.V.B., C.A., A.C.J., K.M.B., J.W.H., T.M.E., C.-J.X., R.-C.H., D.A.V.D., M.W., S.K.M., V.U., F.I.R., J.L., J.V.D., S.A.S.L., T.G.R., M.C.M., E.A.N., Z.X., L.D., S.Z., W.Z., M.P., D.L.D., O.S., J.H.H., D.D.J., L.G., M.B., P.P., R.O.W., I.H.-P., H.Z., M.R.K., U.G., C.J.M., L.J.B., J.M.V., M.-R.J., A.B., A.K.Ö., S.E., P.M.V., S.E.M., G.W., A.R.L.S., S.E.H., T.I.A.S., J.A.T., K.R., I.V.Y., K.K., T.S.N., M.J.S., Y.Y.G., L.R., M.K., A.A.L., B.E., K.H., H.M., R.L.M., T.D., M.V., L.B., A.A.B., L.A.C., W.K., D.A., M.d.V., S.S., J.K., R.K., S.H.A., E.H., M.N.R., D.I.B., A.P.F., C.J.N., E.G., M.M., M.D.F., E.M., A.M.P., E.K., C.A., E.O., D.D., H.M.B., P.E.M., R.J.W., G.H.K., L.T., M.-F.H., J.S., M.C.M.-K., S.K.M., E.C., J.W., N.H., Z.H., E.B.B., G.D.S., V.W.V.J., R.T.L., W.N., S.J.L., D.A.L., C.L.R., H.S., J.F.F.) read and critically revised subsequent drafts.

Additional information

Supplementary Information accompanies this paper at <https://doi.org/10.1038/s41467-019-09671-3>.

Competing interests: The authors declare no competing interests.

Reprints and permission information is available online at <http://npg.nature.com/reprintsandpermissions/>

Journal peer review information: *Nature Communications* thanks the anonymous reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2019

Leanne K. Küpers^{1,2,3,4}, Claire Monnereau^{5,6,7}, Gemma C. Sharp^{1,8}, Paul Yousefi^{1,2,9}, Lucas A. Salas^{10,11}, Akram Ghantous¹², Christian M. Page^{13,14}, Sarah E. Reese¹⁵, Allen J. Wilcox¹⁵, Darina Czamara¹⁶, Anne P. Starling¹⁷, Alexei Novoloaca¹², Samantha Lent¹⁸, Ritu Roy^{19,20}, Cathrine Hoyo^{21,22}, Carrie V. Breton²³, Catherine Allard²⁴, Allan C. Just²⁵, Kelly M. Bakulski²⁶, John W. Holloway^{27,28}, Todd M. Everson²⁹, Cheng-Jian Xu^{30,31}, Rae-Chi Huang³², Diana A. van der Plaats³³, Matthias Wielscher³⁴, Simon Kebede Merid³⁵, Vilhelmina Ullemar³⁶, Faisal I. Rezwan²⁸, Jari Lahti^{37,38}, Jenny van Dongen³⁹, Sabine A.S. Langie^{40,41,42}, Tom G. Richardson^{1,2}, Maria C. Magnus^{1,2,13}, Ellen A. Nohr⁴³, Zongli Xu⁴⁴, Liesbeth Duijts^{4,44,45}, Shanshan Zhao⁴⁶, Weiming Zhang⁴⁷, Michelle Plusquin^{48,49}, Dawn L. DeMeo⁵⁰, Olivia Solomon⁸, Joosje H. Heimovaara³, Dereje D. Jima^{22,51}, Lu Gao²³, Mariona Bustamante^{11,52,53,54}, Patrice Perron^{24,55}, Robert O. Wright²⁵, Irva Hertz-Picciotto⁵⁶, Hongmei Zhang⁵⁷, Margaret R. Karagas^{10,58}, Ulrike Gehring⁵⁹, Carmen J. Marsit²⁹, Lawrence J. Beilin⁶⁰, Judith M. Vonk³³, Marjo-Riitta Jarvelin^{34,61,62,63}, Anna Bergström^{35,64}, Anne K. Örtqvist³⁶, Susan Ewart⁶⁵, Pia M. Villa⁶⁶, Sophie E. Moore^{67,68}, Gonneke Willemsen³⁹, Arnout R.L. Standaert⁴⁰, Siri E. Håberg¹³, Thorkild I.A. Sørensen^{1,69,70}, Jack A. Taylor¹⁵, Katri Räikkönen³⁸, Ivana V. Yang⁷¹, Katerina Kechris⁴⁵, Tim S. Nawrot^{48,72}, Matt J. Silver⁶⁷, Yun Yun Gong⁷³, Lorenzo Richiardi^{74,75}, Manolis Kogevinas^{11,53,54,76}, Augusto A. Litonjua⁵⁰, Brenda Eskenazi^{9,77}, Karen Huen⁹, Hamdi Mbarek⁷⁸, Rachel L. Maguire^{21,79}, Terence Dwyer⁸⁰, Martine Vrijheid^{11,53,54}, Luigi Bouchard^{81,82}, Andrea A. Baccarelli^{83,84}, Lisa A. Croen⁸⁵, Wilfried Karmaus⁵⁷, Denise Anderson³², Maaïke de Vries³³, Sylvain Sebert^{61,62,86}, Juha Kere^{87,88,89}, Robert Karlsson³⁶, Syed Hasan Arshad^{27,90}, Esa Hämäläinen⁹¹, Michael N. Routledge⁹², Dorret I. Boomsma^{39,93}, Andrew P. Feinberg⁹⁴, Craig J. Newschaffer⁹⁵, Eva Govarts⁴⁰, Matthieu Moisse^{96,97}, M. Daniele Fallin⁹⁸, Erik Melén^{35,99}, Andrew M. Prentice⁶⁷, Eero Kajantie^{100,101,102}, Catarina Almquist^{36,103}, Emily Oken¹⁰⁴, Dana Dabelea¹⁰⁵, H. Marike Boezen³³, Phillip E. Melton^{106,107}, Rosalind J. Wright²⁵, Gerard H. Koppelman³⁰, Letizia Trevisi¹⁰⁸, Marie-France Hivert^{55,104,109}, Jordi Sunyer^{11,53,54,76}, Monica C. Munthe-Kaas^{110,111}, Susan K. Murphy¹¹², Eva Corpeleijn³, Joseph Wiemels¹¹³, Nina Holland⁹, Zdenko Herceg¹², Elisabeth B. Binder^{16,114}, George Davey Smith^{1,2}, Vincent W.V. Jaddoe^{5,6,7}, Rolv T. Lie^{13,115}, Wenche Nystad¹¹⁶, Stephanie J. London¹⁵, Debbie A. Lawlor^{1,2}, Caroline L. Relton^{1,2}, Harold Snieder³ & Janine F. Felix^{5,6,7}

¹MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK. ²Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. ³University of Groningen, University Medical Center Groningen, Department of Epidemiology, Groningen, The Netherlands. ⁴Division of Human Nutrition and Health, Wageningen University, Wageningen, The Netherlands. ⁵The Generation R Study Group, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. ⁶Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. ⁷Department of Pediatrics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. ⁸School of Oral and Dental Sciences, University of Bristol, Bristol, UK. ⁹Children's Environmental Health Laboratory, Division of Environmental Health Sciences, School of Public Health, University of California, Berkeley, CA, USA. ¹⁰Department of Epidemiology, Geisel School of Medicine at Dartmouth College, Hanover, NH, USA. ¹¹ISGlobal, Barcelona Institute for Global Health, Barcelona, Spain. ¹²Epigenetics Group, International Agency for Research on Cancer, Lyon, France. ¹³Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway. ¹⁴Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital, Oslo, Norway. ¹⁵Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Research Triangle Park, Durham, NC, USA. ¹⁶Department of Translational Research in Psychiatry, Max-Planck-Institute of Psychiatry, Munich, Germany. ¹⁷Department of Epidemiology, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. ¹⁸Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA. ¹⁹HDF Comprehensive Cancer Center, University of California, San Francisco, CA, USA. ²⁰Computational Biology and Informatics, UCSF, San Francisco, CA, USA. ²¹Department of Biological Sciences, North Carolina State University, Raleigh, NC, USA. ²²Center for Human Health and the Environment, North Carolina State University, Raleigh, NC, USA. ²³Department of Preventive Medicine, University of Southern California, Los Angeles, CA 90089, USA. ²⁴Centre de recherche du Centre hospitalier universitaire de Sherbrooke, Sherbrooke, QC, Canada. ²⁵Department of Environmental Medicine and Public Health, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ²⁶Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI, USA. ²⁷Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK. ²⁸Human Development and Health, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, UK. ²⁹Department of Environmental Health, Rollins School of Public Health at Emory University, Atlanta, GA, USA. ³⁰University of Groningen, University Medical Center Groningen, Department of Pediatric Pulmonology and Pediatric Allergology, Beatrix Children's Hospital, Groningen Research Institute for Asthma and COPD, Groningen, The Netherlands. ³¹University of Groningen, University Medical Center Groningen, Department of Genetics, Groningen, The Netherlands. ³²Telethon Kids Institute, University of Western Australia, Perth, Australia. ³³University of Groningen, University Medical Center Groningen, Department of Epidemiology and Groningen Research Institute for Asthma and

COPD (GRIAC), Groningen, The Netherlands. ³⁴Department of Epidemiology and Biostatistics, MRC-PHE Centre for Environment & Health, School of Public Health, Imperial College London, London, UK. ³⁵Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. ³⁶Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. ³⁷Helsinki Collegium for Advanced Studies, University of Helsinki, Helsinki, Finland. ³⁸Department of Psychology and Logopedics, Faculty of Medicine, University of Helsinki, Helsinki, Finland. ³⁹Department of Biological Psychology, Netherlands Twin Register, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. ⁴⁰VITO - Health, Mol, Belgium. ⁴¹Theoretical Physics, Faculty of Sciences, Hasselt University, Hasselt, Belgium. ⁴²Centre for Environmental Sciences, Hasselt University, Hasselt, Belgium. ⁴³Research Unit for Gynaecology and Obstetrics, Department of Clinical Research, University of Southern Denmark, Odense, Denmark. ⁴⁴Department of Pediatrics, Division of Respiratory Medicine and Allergy, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. ⁴⁵Department of Pediatrics, Division of Neonatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. ⁴⁶Biostatistics and Computational Biology Branch, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, Durham, NC, USA. ⁴⁷Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. ⁴⁸Centre for Environmental Sciences, Hasselt University, Diepenbeek, Belgium. ⁴⁹MRC/PHE Centre for Environment and Health School of Public Health Imperial College London, St Mary's Campus, Norfolk Place, London, UK. ⁵⁰Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. ⁵¹Bioinformatics Research Center, North Carolina State University, Raleigh, NC, USA. ⁵²Bioinformatics and Genomics Program, Centre for Genomic Regulation (CRG), Barcelona, Spain. ⁵³Universitat Pompeu Fabra (UPF), Barcelona, Spain. ⁵⁴CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain. ⁵⁵Department of Medicine, Université de Sherbrooke, Sherbrooke, QC, Canada. ⁵⁶Department of Public Health Sciences, School of Medicine, University of California Davis MIND Institute, Sacramento, CA, USA. ⁵⁷Division of Epidemiology, Biostatistics and Environmental Health, School of Public Health, University of Memphis, Memphis, TN, USA. ⁵⁸Children's Environmental Health & Disease Prevention Research Center at Dartmouth, Hanover, NH, USA. ⁵⁹Institute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands. ⁶⁰Medical School, University of Western Australia, Perth, Australia. ⁶¹Center for Life Course Health Research, Faculty of Medicine, University of Oulu, 90014 Oulu, Finland. ⁶²Biocenter Oulu, University of Oulu, Oulu, Finland. ⁶³Unit of Primary Care, Oulu University Hospital, Oulu, Finland. ⁶⁴Center for Occupational and Environmental Medicine, Stockholm County Council, Stockholm, Sweden. ⁶⁵College of Veterinary Medicine, Michigan State University, East Lansing, MI, USA. ⁶⁶Obstetrics and Gynaecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. ⁶⁷Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine, London, UK. ⁶⁸Department of Women and Children's Health, King's College London, London, UK. ⁶⁹Novo Nordisk Foundation Center for Basic Metabolic Research, Section of Metabolic Genetics, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. ⁷⁰Department of Public Health, Section of Epidemiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. ⁷¹Division of Biomedical Informatics and Personalized Medicine, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. ⁷²Department of Public Health & Primary Care, Leuven University, Leuven, Belgium. ⁷³School of Food Sciences and Nutrition, University of Leeds, Leeds, UK. ⁷⁴Department of Medical Sciences, University of Turin, Turin, Italy. ⁷⁵AOU Città della Salute e della Scienza, CPO Piemonte, Turin, Italy. ⁷⁶IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. ⁷⁷Center for Environmental Research and Children's Health, School of Public Health, University of California, Berkeley, CA, USA. ⁷⁸Department of Biological Psychology, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. ⁷⁹Department of Community and Family Medicine, Duke University Medical Center, Raleigh, NC, USA. ⁸⁰The George Institute for Global Health, Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford, UK. ⁸¹Department of Biochemistry, Université de Sherbrooke, Sherbrooke, QC, Canada. ⁸²ECOGENE-21 Biocluster, Chicoutimi Hospital, Saguenay, QC, Canada. ⁸³Laboratory of Precision Environmental Biosciences, Columbia University Mailman School of Public Health, New York, NY, USA. ⁸⁴Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY, USA. ⁸⁵Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA. ⁸⁶Department for Genomics of Common Diseases, School of Public Health, Imperial College London, London, UK. ⁸⁷Folkhälsan Institute of Genetics, Helsinki, and Research Programs Unit, Molecular Neurology, University of Helsinki, Helsinki, Finland. ⁸⁸Department of Biosciences and Nutrition, Karolinska Institutet, Huddinge, Sweden. ⁸⁹School of Basic and Medical Biosciences, King's College London, Guy's Hospital, London, UK. ⁹⁰David Hide Asthma and Allergy Research Centre, Isle of Wight, UK. ⁹¹HUSLAB and the Department of Clinical Chemistry, University of Helsinki, Helsinki, Finland. ⁹²LICAMM, School of Medicine, University of Leeds, Leeds, UK. ⁹³Amsterdam Public Health Institute, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. ⁹⁴Center for Epigenetics, Johns Hopkins University School of Medicine, Baltimore, MA, USA. ⁹⁵AJ Drexel Autism Institute, Drexel University, Philadelphia, PA, USA. ⁹⁶KU Leuven - University of Leuven, Department of Neurosciences, Experimental Neurology and Leuven Institute for Neuroscience and Disease (LIND), Leuven, Belgium. ⁹⁷VIB, Center for Brain & Disease Research, Laboratory of Neurobiology, Leuven, Belgium. ⁹⁸Department of Mental Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA. ⁹⁹Sachs' Children's Hospital, Stockholm, Sweden. ¹⁰⁰National Institute for Health and Welfare, Helsinki and Oulu, Oulu, Finland. ¹⁰¹Hospital for Children and Adolescents, Helsinki University Hospital and University of Helsinki, Helsinki, Finland. ¹⁰²PEDEGO Research Unit, MRC Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland. ¹⁰³Pediatric Allergy and Pulmonology Unit at Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden. ¹⁰⁴Department of Population Medicine, Harvard Medical School, Harvard Pilgrim Health Care Institute, Boston, MA, USA. ¹⁰⁵Department of Epidemiology, Colorado School of Public Health, and Department of Pediatrics, University of Colorado School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. ¹⁰⁶Centre for Genetic Origins of Health and Disease, School of Biomedical Sciences, University of Western Australia, Perth, Australia. ¹⁰⁷School of Pharmacy and Biomedical Sciences, Curtin University, Perth, Australia. ¹⁰⁸Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA. ¹⁰⁹Diabetes Unit, Massachusetts General Hospital, Boston, MA, USA. ¹¹⁰Norwegian Institute of Public Health, Oslo, Norway. ¹¹¹Department of Pediatric Oncology and Hematology, Oslo University Hospital, Oslo, Norway. ¹¹²Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC, USA. ¹¹³Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA. ¹¹⁴Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA. ¹¹⁵Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway. ¹¹⁶Department for Non-Communicable Diseases, Norwegian Institute for Public Health, Oslo, Norway. These authors jointly supervised this work: Debbie A. Lawlor, Caroline L. Relton, Harold Snieder, Janine F. Felix.